Extended Data Fig. 4: Liver safety monitoring of a human PCSK9 epigenetic editor in cynomolgus monkeys. | Nature Medicine

Extended Data Fig. 4: Liver safety monitoring of a human PCSK9 epigenetic editor in cynomolgus monkeys.

From: A potent epigenetic editor targeting human PCSK9 for durable reduction of low-density lipoprotein cholesterol levels

Extended Data Fig. 4: Liver safety monitoring of a human PCSK9 epigenetic editor in cynomolgus monkeys.

Serial measurements of blood alanine transaminase (a), aspartate transaminase (b), and total bilirubin (c) were performed in non-human primates following dosing with either a vehicle control or PCSK9-EE-V2. Results are shown as mean ± s.d. (n = 4 animals in vehicle group and n = 3 animals in each experimental group receiving PCSK9-EE-V2). Plasma samples were obtained from two of the vehicle-treated animals at day 84 and 98. These data have been averaged and plotted at day 91 to better visualize the group mean.

Back to article page